CSF

VictoryShares US Discovery Enhanced Volatility Wtd ETF (CSF) | Rumor.io

VictoryShares US Discovery Enhanced Volatility Wtd ETF

CSF

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)61%

Price to earnings ratio0

Net assets0

Expense ratio0%

Social

What share of all ETF conversation is about CSF?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% +0

Dec 3

CSF GCase activity showed a ~53% increase in a Phase 1a trial, indicating potential for a disease-modifying treatment in Parkinson's.
Gain Therapeutics is largely de-risked and close to releasing compelling evidence, making it a prime target for partnership or acquisition.
The company has a rare set-up, with a largely de-risked profile and strong Phase 1a results, positioning it for potential success in the biotech space.

Generated by AI

Sentiment

Of the messages about CSF that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +75.68	69.75% -30.25
Bearish	—	—	0% -75.68	30.25% +30.25

Bullish· Oct 4

$CSF is experiencing explosive growth, with over 100 million views on TikTok within a few days.
The asset has strong conviction from the community, with a great story and active participation.
$CSF is expected to continue its upward trend, with potential for explosive growth as more people discover and engage with it.

Bearish· Jun 30

The UK may show faster approval for HGEN's GM-CSF treatment due to the raging variant.
The UK's NICE has already reached out to HGEN for EUA, indicating potential interest.
The UK's approval process may be as favorable or even more favorable than the US.

Generated by AI

Topics

Of the messages about CSF that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Macro	—	—	—	0%
Technical Analysis	—	—	—	100%

Community

Of the messages about CSF, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	25%	25%	0.23%	11.1%
Newcomers	75%	75%	99.77%	88.9%

Dec 3

Newcomers are excited about Gain Therapeutics ($GANX) due to its potential in treating Parkinson's disease, citing a rare setup with de-risked conditions and upcoming evidence of a disease-modifying treatment.
The Phase 1a trial results showed clean safety, clear CNS penetration, and a 53% increase in CSF GCase activity, which is seen as a promising development.
Gain Therapeutics' setup is considered prime for partnership or acquisition, with a potential for significant impact in the biotech industry.

Generated by AI

Also Discussed

Investors talking about CSF also mention

#	Name	Attention
1	IMV - IMV Inc.	——
2	Carpenter Technology CorporationCRS	0%new
3	Gain Therapeutics, Inc.GANX	0.04%+0.02
4	BeyondSpring Inc.BYSI	0%0
5	Plus Therapeutics IncPSTV	0%0
6	Hercules Capital Inc. Preferred Stock 6.25% 10/30/33HCXY	0%new
7	SPPI - Spectrum Pharmaceuticals, Inc.	——
8	BCLI - Brainstorm Cell Therapeutics Inc.	——
9	DDC Enterprise Limited Class A Ordinary SharesDDC	0%new
10	Fulcrum Therapeutics, Inc.FULC	0%0